AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00477802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Injected once during the course of the study.
Study NCT00477802 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected once during the course of the study.
Study NCT03779347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel to treat schistosomiasis during pregnancy
Study NCT03779347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Praziquantel to treat schistosomiasis during pregnancy
Study NCT03779347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UCP-LF CAA
Description: UCP-LF CAA to diagnose Schistosomiasis during pregnancy
Study NCT03779347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: composite diagnostic
Description: composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
Study NCT03513679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgery to decompress the spinal cord, either with or without concurrent fusion
Study NCT01211756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID for one week, followed by 40 IU BID for 3 weeks.
Study NCT01211756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 IU BID for one week, followed by 40 IU BID for 3 weeks.
Study NCT02686164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
Study NCT02686164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
Study NCT01091246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q/LAIV (MEDI3250)
Description: 10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
Study NCT01091246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist/B/Yamagata
Description: 10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
Study NCT01091246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist/B/Victoria
Description: 10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
Study NCT04226781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperspectral-Imaging
Description: Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
Study NCT04226781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyaningreen-Fluorescence imaging
Description: Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
Study NCT03002636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
Study NCT03002636 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: anesthesia
Description: Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
Study NCT03421938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
Study NCT05148637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of general anesthesia by Sevoflurane
Description: Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
Study NCT00981136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Incision Laparoscopic Appendectomy
Description: A single incision through the umbilicus to remove the appendix
Study NCT00981136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 port laparoscopic appendectomy
Description: Standard 3 port laparoscopic appendectomy with intracorporeal stapling
Study NCT02649504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
Study NCT02649504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
Study NCT02649504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
Study NCT02649504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
Study NCT02649504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
Study NCT05148637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of general anesthesia by Desflurane
Description: Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
Study NCT05148637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)
Description: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
Study NCT02649504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
Study NCT04343976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda
Description: 180 mcg subcutaneous injection of pegylated interferon lambda
Study NCT04343976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon lambda
Description: 180 mcg subcutaneous injection of pegylated interferon lambda
Study NCT00911768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng Powder Capsule
Description: Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
Study NCT00911768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn-starch powder with ginseng flavor
Description: There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor
Study NCT01909297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROSEAL LMA
Description: Size 3,4 or 5 supraglottic device with orogastric drainage tube
Study NCT01909297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUPREMA LMA
Description: Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
Study NCT01909297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-GEL LMA
Description: Size 3,4,5 disposable supraglottic device with noninflatable cuff
Study NCT04265326 — intervention group
Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
Study NCT04158804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: procalcitonin
Description: accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
Study NCT03759782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
Study NCT03759782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir as per standard of care
Study NCT03621033 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonic transendoscopic enteral tubing
Description: The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
Study NCT02874313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
Study NCT02874313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with oral antidiabetic drugs or insulin
Study NCT03759782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir as per standard of care
Study NCT00613899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telesurveillance
Description: A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin-omeprazole
Description: Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin-pantoprazole
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin-esomeprazole
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin-ranitidine
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin-omeprazole
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin-pantoprazole
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin-esomeprazole
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
Study NCT00930670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin-ranitidine
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
Study NCT01883102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1%
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
Study NCT01883102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
Study NCT03655743 — intervention group
Intervention type: DEVICE
Intervention: LASIK, PRK, Phacoemulsification
Description: Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification
Study NCT02360735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
Study NCT02360735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All patients will participate in joint physical therapy classes during their inpatient stay.
Study NCT02360735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: All patients will participate in joint physical therapy classes during their inpatient stay.
Study NCT03406078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT03406078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT02874313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with oral antidiabetic drugs or insulin
Study NCT02874313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional anti-diabetic diet recommendations
Study NCT02874313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anti-diabetic diet recommendations
Study NCT01673178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
Study NCT01673178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg PF-05231023
Description: 25 mg IV once a week for 4 weeks
Study NCT00831662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium ophthalmic solution, 2%
Description: One to two drops in each eye QID for 6 weeks
Study NCT00831662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One to two drops in each eye QID for 6 weeks
Study NCT02720120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Study NCT02720120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single IV infusion of placebo.
Study NCT01413503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
Study NCT01675453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5
Study NCT01675453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study NCT03686423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
Study NCT01673178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PF-05231023
Description: 50 mg IV once a week for 4 weeks
Study NCT01673178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PF-05231023
Description: 100 mg IV once a week for 4 weeks
Study NCT01673178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg PF-05231023
Description: 150 mg IV once a week for 4 weeks
Study NCT04474886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresubin® powder fibre
Description: 2 servings per day
Study NCT02246153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy.
Study NCT02246153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience.
Study NCT04137289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711
Study NCT03724357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxchora
Description: One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
Study NCT00331838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.8 mL solution in Type I amber glass vials~Subcutaneous injection
Study NCT00331838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Enoxaparin sodium)
Description: 0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study NCT00331838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection
Study NCT00331838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Semuloparin sodium)
Description: 0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study NCT00331838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Semuloparin sodium)
Description: 0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study NCT00254553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim 1% (testosterone gel)
Description: Testim_ 100 mg: two tubes of 50 mg of Testim_per day
Study NCT00254553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tubes of placebo per day
Study NCT00280592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
Study NCT00280592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
Study NCT02712957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO6860
Description: TRPV1 antagonist
Study NCT02712957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEO6860 placebo
Description: Inactive substance
Study NCT02712957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NEO6860 placebo
Description: Inactive substance
Study NCT02712957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: NSAID
Study NCT02712957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen placebo
Description: inactive substance